The list · strictly business
The rest of the site flirts. This list doesn't.
What each peptide does, how it works, and where it stands with the FDA. Click any one to learn more.
HHS Secretary Kennedy's April 2026 withdrawal list named these 12 peptides for PCAC re-evaluation beginning July 2026. The outcome isn't final. Reclassification to Category 1 would lift the enforcement risk compounding pharmacies currently face and broaden access by easing physician hesitancy about prescribing.
A tripeptide-copper complex that supports skin regeneration and wound healing.
Naturally occurring in plasma; levels decline with age. Widely used in topical and compounded formulations.
A 15-residue peptide derived from gastric juice, used for tissue and gut repair.
Most studied for tendon, ligament, and GI recovery; controlled human data remains limited.
A 43-residue peptide involved in actin dynamics, angiogenesis, and tissue repair.
Marketed as TB-500 in fragment form; angiogenesis mechanism raised tumor-growth concerns during FDA review.
A 16-residue mitochondrial-derived peptide involved in metabolic and exercise signaling.
Encoded in mitochondrial DNA; studied for insulin sensitivity and age-related metabolic decline.
A 7-residue ACTH(4-7) analog studied for memory, focus, and nerve regeneration.
Russian-origin neuropeptide approved in Russia for stroke recovery; evidence base is largely outside the Western literature.
An orally active angiotensin IV-derived peptidomimetic studied for synaptogenesis and cognition.
No published human clinical trials; the evidence base remains preclinical and animal-model driven.
A 4-residue peptide studied for telomerase activation and pineal-axis modulation.
Russian-origin longevity peptide; most clinical data comes from Russian institutes with methodological limitations.
A 9-residue neuropeptide that promotes deep sleep and modulates the stress response.
Discovered in the 1970s; research has remained sparse and controlled human safety data is limited.
A 3-residue α-MSH fragment with selective anti-inflammatory activity.
Studied for IBD, colitis, and wound healing; acts independently of melanocortin receptor binding.
A cyclic 7-residue melanocortin agonist that induces pigmentation and drives libido.
Regulators cite serious safety risks including potential melanoma induction and sympathomimetic toxicity.
An orally active ghrelin receptor agonist that elevates growth hormone and IGF-1.
A non-peptide small molecule marketed alongside peptides; named in the April 2026 HHS Category 2 withdrawal for PCAC re-evaluation.
A 37-residue antimicrobial peptide from the human cathelicidin family.
Broad roles in innate immunity and wound healing; named in the April 2026 HHS Category 2 withdrawal for PCAC re-evaluation.
FDA-approved drugs available via standard prescription, or Category 1 substances that licensed compounding pharmacies can legally prepare today.
A cyclic 7-residue melanocortin receptor agonist that acts centrally to drive arousal.
FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder.
A mitochondria-targeted tetrapeptide that stabilizes cardiolipin to support cellular energy.
FDA-approved as Forzinity for Barth syndrome in 2025; the first mitochondria-targeted therapeutic approved.
A GLP-1 receptor agonist that slows gastric emptying and reduces appetite signaling.
Approved as Ozempic and Wegovy for diabetes and chronic weight management; compounding increasingly restricted.
A dual GIP and GLP-1 receptor agonist developed for diabetes and weight management.
Approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management.
A linear α-MSH analog that selectively activates MC1R to drive photoprotective pigmentation.
FDA-approved as Scenesse, a subcutaneous implant used in erythropoietic protoporphyria.
A stabilized 44-residue GHRH analog that stimulates endogenous growth hormone secretion.
FDA-approved as Egrifta for HIV-associated lipodystrophy; strongest clinical evidence of the GHRH analog family.
A tripeptide-copper complex that supports skin regeneration and wound healing.
Naturally occurring in plasma; levels decline with age. Widely used in topical and compounded formulations.
A 29-residue GHRH analog that prompts the pituitary to release endogenous growth hormone.
Formerly marketed as Geref for pediatric GH deficiency; discontinued in 2008 for commercial reasons.
A tripeptide antioxidant central to cellular redox, detoxification, and immune function.
Produced endogenously and supplemented via IV, injection, or oral routes; clinical evidence remains mixed.
These peptides are either in FDA Category 2 without a pending reclassification, or are not listed on any FDA bulk drug substances list.
A 28-residue peptide that modulates T-cell maturation and innate immune signaling.
Approved outside the U.S. for chronic hepatitis; domestic compounding remains ineligible after PCAC review.
A stabilized GHRH analog designed to extend the half-life of natural growth hormone pulses.
Widely compounded before 2023; currently flagged by FDA for aggregation and immunogenicity concerns.
A selective ghrelin receptor agonist that prompts GH release without cortisol or prolactin effects.
Studied for body composition and recovery; ineligible for 503A compounding following the FDA PCAC safety review.
A modified fragment of human growth hormone (residues 176 to 191) studied for fat metabolism.
Isolates the lipolytic region of hGH; FDA cited immunogenicity and serious adverse events during review.
A 7-residue tuftsin analog with anxiolytic and cognitive-support properties.
Russian-origin neuropeptide approved in Russia as Selank; no FDA-recognized clinical evidence in the U.S.
A 10-residue peptide that activates KISS1R to trigger GnRH and reproductive hormone release.
Central regulator of the hypothalamic-pituitary-gonadal axis; studied for IVF induction and hypogonadism diagnosis.
A copper-bound tripeptide that stimulates fibroblast proliferation and follicle signaling.
Used in cosmetic and hair-regeneration formulations; not on any FDA bulks list for compounding.
A D-retro-inverso peptide that disrupts FOXO4 and p53 binding to clear senescent cells.
Preclinical senolytic tool studied in mouse aging models; no published human trials and no bulks-list listing.
A long-acting IGF-1 analog with an N-terminal extension and Arg3 substitution.
Half-life extended to roughly 20 hours; safety literature flags severe hypoglycemia and tumor-growth risks.